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Patients with severe von Willebrand disease (VWD) may developarthropathy after joint bleeds.  Information  on its prevalence andseverity is limited. We aimed to assess the occurrence and severity
of arthropathy in VWD and its impact on daily life. VWD patients with
and without verified joint bleeds were matched for age, sex and Factor
VIII level or von Willebrand Factor activity in a nested case-control study
within the Willebrand in the Netherlands study. Assessments included
the  Hemophilia Joint Health Score (0-124), Pettersson score (0-13 per
joint X-ray), Hemophilia Activity List score (0-100),  joint pain (Visual
Analog Scale 0-10), and the Impact on Participation and Autonomy ques-
tionnaire (0-20). Arthropathy was defined as a Hemophilia Joint Health
Score of 10 or higher, or a Pettersson score over 3 of at least one joint.
We included 48 patients with verified joint bleeds (cases) and 48 con-
trols: 60% males, mean age 46 years (range 18-80), median von
Willebrand Factor activity 5 versus 8 IU/dL and Factor VIII 24 versus 36
IU/dL. Arthropathy occurred in 40% of the cases versus 10% of the con-
trols (P<0.01). The cases reported more functional limitations compared
to the controls (median Hemophilia Activity List score: 88 vs. 100,
P<0.01). Arthropathy was related to joint pain and less social participa-
tion (Visual Analog Scale>3: 13 of 19  vs. 3 of 28, P<0.01, and median
score on the participation questionnaire 6.1  vs. 0.9, P<0.01). In conclu-
sion, arthropathy occurs in 40% of VWD patients after joint bleeds and
is associated with pain, radiological abnormalities, functional limita-
tions, and less social participation (Dutch trial register: NTR4548).
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ABSTRACT
Introduction 
Von Willebrand disease (VWD) is a congenital bleeding disorder with a popula-
tion prevalence of 0.6-1.3%.1 VWD is caused by a deficiency (type 1), dysfunction
(type 2) or absence (type 3) of von Willebrand factor (VWF) and is mainly associ-
ated with mucocutaneous bleeding and menorrhagia. Joint bleeds also occur in
VWD, predominantly in severely affected patients with
concomitant low Factor VIII levels (FVIII).2 Low FVIII
occurs because its chaperone protein VWF, which protects
FVIII from degradation, is (partly) missing. In hemophilia
patients with FVIII or FIX deficiency, recurrent joint bleeds
are the main cause of pain and functional limitations,
which is known as hemophilic arthropathy.3 Joint bleeding
occurs in half of the patients with type 3 VWD and in 5-
10% of moderate and severe type 1 and type 2 VWD
patients.4 However, hardly any information is available on
the existence and severity of blood-induced arthropathy
in VWD.5
There are no data on joint health and the influence of
arthropathy on daily life activities in VWD.5 In the
Willebrand in the Netherlands (WiN) study, almost a quar-
ter of the patients reported joint bleeds. These joint bleeds
appeared to have a negative impact on health-related qual-
ity of life and joint integrity, according to self-reported and
retrospective medical file data.4 To describe and measure
health and disability, the World Health Organization's
(WHO) International Classification of Functioning,
Disability and Health (ICF) standard has been endorsed.
This standard focuses on impact rather than cause of dis-
ability, including functioning and participation, as well as
environmental and personal factors.6 It is, therefore, useful
to study the consequences of joint bleeds in VWD within
this broad ICF perspective. 
It is important to assess joint outcome after joint bleeds
in order to find and implement optimal treatment strate-
gies that prevent or diminish arthropathy.7 The primary
objective of this nested case-control study is to assess both
occurrence and severity of arthropathy in patients with
VWD after joint bleeds (ICF domain on body structure
and function), compared to VWD patients without clini-
cally overt joint bleeding, and to compare self-perceived
functional abilities and social participation (ICF domains
on activity and participation) between these two groups.
The secondary objective is to explore a possible associa-
tion between arthropathy and environmental and person-
al factors (ICF contextual factors).
Methods 
Ethical approval was obtained from the medical ethical commit-
tee of the University Medical Center Utrecht, the Netherlands
(Dutch trial register: NTR4548).
Study population
A nested case-control study was performed within the national
cohort WiN study between August 2013 and July 2015. Cases
were selected from this WiN study cohort, based on verified joint
bleeds (VWD-JB patients).2,4 Adult patients with VWD according
to the definitions of the WiN study (historically lowest VWF activ-
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Table 1. Baseline characteristics of 48 von Willebrand disease patients treated for joint bleeds and 48 controls.
VWD-JB patients VWD controls
n=48 n=48
Sex Males (n, %)
Females (n, %) 29 (60%)
19 (40%) 29 (60%)
19 (40%)
Age (y) Males (median, range) 45 (18-78) 48 (20-80)
Females (median, range) 48 (18-74) 47 (18-73)
Type VWD* 1 (n, %) 8 (17%) 20 (42%)
2 (n, %) 21 (44%) 25 (52%)
2A (n) 15 17
2B (n) 5 5
2M (n) 0 2
2N (n) 1 1
3 (n, %) 19 (39%) 3 (6%)
Levels (IU/dL; med, IQR)† VWF:Ag 13 (1-36) 22 (12-28)
VWF:Act 5 (0-14) 8 (3-30)
FVIII:C 24 (3-46) 36 (24-54)
Cumulative n. of joint bleeds# No. JB (n, %) 34 (71%)
Once 8 (17%) 9 (19%)
2-5 13 (27%) 5 (10%)
6-10 6 (12%) -
>10 21 (44%) -
Joint bleed treatment VWF concentrate 44 (92%) -
Desmopressin 10 (21%) -
Relevant comorbidity¶ n (%) 3 (6%) 5 (10%)
VWD: von Willebrand disease; JB: joint bleed; n.: number; y: years; med: median; IQR: 25-75% interquartile range;  IU/dL: units per deciliter; VWF:Ag: von Willebrand factor antigen
level; VWF:Act: VWF activity level; FVIII:C: Factor VIII level. *Based on centrally determined [n=94, data from the Willebrand in the Netherlands (WiN) study] or historic VWD type
(n=4, as known in the hemophilia treatment center). †Centrally measured: based on 72 patients for whom plasma was available at times of WiN inclusion and after exclusion of
pregnant patients and those who had received  clotting factor concentrate (CFC) or desmopressin less than 72 hours before the laboratory assessment. #Based on medical file
data and information provided by the participants during the study visit. ¶5 controls (2 gout, 1 psoriatric arthritis, 1 congenital flexion contraction elbows, 1 elbow fracture) and
3 patients (1 septic arthritis knee, 1 psoriatric arthritis, 1 ankle fracture).
ity <30 IU/dL8) from all hemophilia treatment centers in the
Netherlands were eligible. Joint bleeds were verified if we found
medical file documentation of treatment with clotting factor or
desmopressin for at least one joint bleed. VWD patients without
prior treated joint bleeds were included as controls (VWD con-
trols). These VWD controls were primarily selected from the WiN
cohort and matched 1:1 to the VWD-JB patients for age, sex and,
if possible, on FVIII or otherwise on VWF activity (Online
Supplementary Table S1).4 The goal of the case-control design was
to distinguish joint bleed-related arthropathy from other causes of
joint deterioration, such as age-related osteoarthritis or subclinical
joint bleeding. The absence of documented treatment for joint
bleeds in the medical files at inclusion was regarded as “no clini-
cally relevant joint bleeds”. Exclusion criteria were inability to give
informed consent, recent joint bleeding without complete recov-
ery, and lack of available medical files. Restricted motion due to
another musculoskeletal disorder [e.g. gout or rheumatoid arthritis
(RA), excluding age-related osteoarthritis] was regarded as rele-
vant musculoskeletal comorbidity.  
Primary outcome parameters for joint health 
assessment 
Participants were invited for a half-day visit to the hemophilia
treatment center, and underwent physical examination and meas-
urements. Joint X-rays were performed. One experienced physio-
therapist conducted the Hemophilia Joint Health score (HJHS, 0-
30/joint, total range 0-124) in all participants. The HJHS has been
developed to analyze joint outcome in hemophilia.9 It is an 11-
item scoring tool to assess joint health of elbows, knees and ankles
that includes range of motion, crepitus on motion, swelling, mus-
cle atrophy, pain, joint strength, and global gait. Range of motion
reference values to calculate the HJHS were derived from Soucie et
al.10 For the analyses, we dichotomized the HJHS≥10 as ‘arthropa-
thy’ based on our interobserver reliability results in VWD and
because this cut-off value has also been used in hemophilia to
define arthropathy.11,12 
X-rays were taken from all ankles, knees and elbows with prior
bleeds, the contralateral joints of the VWD-JB patients, and from
the ipsilateral joints of the matched VWD controls. X-rays were
scored by one radiologist according to Pettersson (PS, 0-13 points
per joint), using a consensus atlas.13 We defined a PS>3 of one or
more joints as ‘radiological arthropathy’, based on the Limits of
Agreement of the PS joint in hemophilia patients.14
All participants were asked to complete the Hemophilia
Activity List (HAL, normalized score: 0-100). This questionnaire
has been developed to analyze self-perceived functional abilities in
hemophilia.15,16 The HAL total and three component sub scores
[‘upper extremity activities’ (HAL upper), ‘basic lower extremity
activities’ (HAL lowbas) and ‘complex lower extremity activities’
(HAL lowcom)] were calculated. A score of 100 means no func-
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Table 2. Arthropathy, functional abilities and contextual factors compared between the von Willebrand disease-joint bleeds (VWD-JB) patients and
VWD controls. 
VWD-JB patients VWD controls P
n=48 n= 48
Mean CFC use* Median IU FVIII/kg/y (IQR) 51 (1.3-188) 0 (0-0) <0.01
CFC prophylaxis¶ n (%) 13 (27%) 1 (2%) <0.01
because of JB n (%) 11 (23%) -
Surgery in large joints‡ Overall n (%) 22 (46%) 10 (21%) <0.01
Because of JB n (%) 9 (19%) - -
BMI Mean (range) 26 (18-49) 25 (17-37) 0.28
HJHS total Median (IQR) 5 (1-15) 1.5 (0-5) <0.01
HJHS ≥ 10 n (%) 19 (40%) 5 (10%) <0.01
PS >3 n (%) 12 (25%) 2 (4%) <0.01
PS >3 ankle n (%) 9 (19%) 1 (2%) <0.01
PS >3 knee n (%) 5 (10%) 1 (2%) 0.09
PS >3 elbow n (%) 2 (4%) 0 0.15
HAL total Median (IQR) 88 (69-98) 100 (87-100) <0.01
HAL upper Median (IQR) 93 (82-100) 100 (91-100) 0.01
HAL lowbas Median (IQR) 87 (53-100) 100 (86-100) <0.01
HAL lowcom Median (IQR) 80 (44-100) 100 (77-100) <0.01
HAL total <95 n/total (%) 32/48 (67%) 16/46 (35%) <0.01
Figure 8 (sec)
Preferred speed Median (range) 15 (10-25) 14 (11-24) 0.24
Maximum speed Median (range) 11 (8-20) 10 (8-20) 0.71
Joint pain§ Overall n (%) 29 (60%) 23 (48%) 0.22
VAS mean ** Median (IQR) 3.5 (1-5.7) 2.1 (1.4-4.7) 0.39
VAS >3 joint n (%) 17 (35%) 9 (19%) 0.07
D-AIMS2affect Anxiety median (range) 13 (7-24) 12 (5-22) 0.33
Mood median (range) 12 (5-22) 9 (5-17) 0.87
IPA Sum score median (range) 1.93 (0-11) 0.97 (0-14) 0.14
VWD: von Willebrand disease; JB: joint bleeds; CFC: clotting factor concentrate; IU: units; IQR: 25-75% interquartile range; BMI: Body Mass Index; HJHS: Hemophilia Joint Health
Score; VAS: Visual Analog Scale pain scale (total range 0-10 cm); PS: Pettersson score; sec: seconds; IPA: Impact on Participation and Autonomy questionnaire. HAL: Hemophilia
Activity List questionnaire; DAIMS2affect: Dutch Arthritis Impact Measurement Scales-2.*In units Factor VIII/kg/year calculated over five years (2005-2009), based on medical file
data (n=90).  ¶Currently or in the past; defined as at least 1 regular CFC infusion per week for at least 45 consecutive weeks. §Chronic joint pain, not related to a recent joint bleed.
‡Knee, ankle, elbow, shoulder or hip surgery. **N=27 patients and n=21 controls.
tional limitations. For statistical analyses, the total HAL score was
dichotomized into ‘no functional limitations’ (>95) and ‘some
functional limitations’ (<95). This threshold was chosen as it was
the median HAL score in patients with severe hemophilia.7 We
recently validated both the HJHS and HAL in VWD.12
Secondary outcome parameters 
All participants were asked to perform the modified Figure 8
walk test17 and to complete the Impact on Participation and
Autonomy questionnaire (IPA, 31 items with 0-4 points per item
on five domains: 0=very good, 4=bad; IPA sum score of mean
scores per item range 0-20).16,18 Participants were also requested to
complete the affect component of the Dutch Arthritis Impact
Measurement Scales-2 (D-AIMS2affect), asking questions on anx-
iety and depression ranging from 5 (never) to 25 (always) for both
components, as well as the McGill Pain Questionnaire-Dutch
Language Version.19,20 The mean Visual Analog Score (VAS 0-10
cm) for pain was calculated from the minimum and maximum
VAS reported in this questionnaire. A mean VAS of more than 3 in
joints (chronic joint pain, not related to a recent joint bleed) was
considered as clinically-relevant joint pain. Body Mass Index 
(BMI)  was calculated after measuring body weight and height
during the study visit. Data on the cumulative number of joint
bleeds, history of joint surgery, use of prophylaxis (defined as at
Long-term impact of joint bleeds in VWD
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Table 3. Characteristics, functional abilities and contextual factors compared within the von Willebrand disease-joint bleed (VWD-JB) patients
with versus without arthropathy (HJHS ≥10 or PS >3 of one or more joints).
VWD-JB and arthropathy VWD-JB no arthropathy P
n=19 n=29
Sex Males (n,%) 7 (37%) 22 (76%) <0.01
Females (n,%) 12 (63%) 7 (24%)
Age (y) (median, range) 50 (28-64) 44 (18-78) 0.38
VWD subtype Type 1 3 5 0.90
Type 2 4 17 0.01
Type 3 12 7 0.01
Levels (IU/dL; med, IQR)† VWF:Ag 1 (0-50) 13 (7-30) 0.75
VWF:Act 0 (0-19) 6 (0-12) 0.90
FVIII:C 5 (1-51) 26 (10-42) 0.36
JB sites & cum n. n (%)
Elbow 6 (32%) 12 (41%)
Elbow >5 JB 2 (11%) 0 0.07
Knee 13 (68%) 25 (86%)
Knee >5 JB 4 (21%) 3 (10%) 0.30
Ankle 16 (84%) 21 (72%)
Ankle >5 JB 13 (68%) 6 (21%) <0.01
Mean CFC use* Median IU FVIII/kg/y 343 (79-821) 18 (0-73) <0.01
(IQR)
CFC prophylaxis¶ n (%) 12 (63%) 1 (3%) <0.01
because of JB n (%) 11 (58%) 0
Surgery in large joints‡ Overall n (%) 12 (63%) 19 (66%) 0.05
Because of JB n (%) 9 (47%) 0 <0.01
HJHS total Median (IQR) 16 (14-26) 2 (0.3-4) <0.01
HAL total Median (IQR) 70 (49-78) 95 (88-100) <0.01
HAL upper Median (IQR) 88 (71-93) 100 (91-100) <0.01
HAL lowbas Median (IQR) 50 (37-83) 97 (87-100) <0.01
HAL lowcom Median (IQR) 53 (24-71) 89 (73-100) <0.01
HAL total <95 n/total (%) 32/48 (67%) 16/46 (35%) <0.01
Figure 8 (sec)
Preferred speed Median (range) 16 (15-20) 14 (13-15) <0.01
Maximum speed Median (range) 12 (11-13) 9.7 (9.2-11) <0.01
Joint pain§ Overall n (%) 17 (89%) 12 (41%) <0.01
VAS mean ** Median (IQR) 3.5 (3.1-6.3) 0.3 (0.0-1.1) <0.01
VAS >3 joint n (%) 13 (68%) 4 (14%) <0.01
D-AIMS2affect Anxiety median (range) 13 (10-17) 13 (10-16) 0.90
Mood median (range) 10 (8-12) 9 (7-11) 0.14
IPA¥ Sum score median (range) 6.1 (2.5-8.6) 0.9 (0-2.4) <0.01
VWD: von Willebrand disease; JB: joint bleeds; y: year; IQR: interquartile range; cum: cumulative;  CFC: clotting factor concentrate; IU: units; n: number: HJHS: Hemophilia Joint
Health Score; HAL: Hemophilia Activity List questionnaire;  VAS: Visual Analog Scale pain scale (total range 0-10 cm). *In units factor VIII/kg/year calculated over five years (2005-
2009), based on medical file data (n=44). ¶or in the past; defined as at least 1 regular CFC infusion per week for at least 45 consecutive weeks. †Centrally measured: based on 34
patients of whom plasma was available at time of Willebrand in the Netherlands (WiN) study inclusion and after exclusion of pregnant patients and those who had received
CFC or desmopressin less than 72 hours before the laboratory assessment. §Chronic joint pain, not related to a recent joint bleed. ‡Knee, ankle, elbow, shoulder or hip surgery.
**Based on n=17 arthropathy patients and n=26 patients without arthropathy. ¥N=12 and n=27, respectively; med: median; sec: seconds; DAIMS2affect: Dutch Arthritis Impact
Measurement Scales-2.
least 1 regular clotting factor infusion per week for at least 45 con-
secutive weeks, currently or in the past), and total clotting factor
use (in units factor VIII/kg/year calculated over 5 years), were
retrieved from the medical files and verified by the principal inves-
tigator (KG) by asking the participants  during the study visit. The
cumulative lifetime number of joint bleeds was categorized as a
history of 0, 1, 2-5, 6-10 or >10 joint bleeds, based on medical file
data and verified by asking the participants during the study visit. 
Sample size
A sample size of 50 VWD-JB patients and 50 VWD controls
would be sufficient to detect a difference in joint function of 8
points in the HJHS, with a power of 80%, and significance level of
5% (2-sided). When the inter-rater variability is taken into
account, differences of more than 7-10 points in the total HJHS are
likely to represent clinically significant differences.12,21,22 With a
sample size of 50 in each group we would be able to detect a dif-
ference of 17% in the proportion of patients with ‘radiological
arthropathy’ and with ‘some functional limitations’, with a power
of 80% and significance level of 5% (1-sided) based on an estimat-
ed prevalence of 5% in the control group. 
Statistical analysis 
For statistical analysis, we used IBM SPSS v.23. To evaluate
normal distribution of continuous scores, we used Q-Q plots.
Mann-Whitney U and χ2 tests were used to compare continuous
values and proportions, respectively. To explore whether BMI,
relevant musculoskeletal comorbidity, and anxiety or mood (D-
AIMS2affect) could explain a difference in HJHS between the
VWD-JB patients and VWD controls, we used multivariable neg-
ative binomial regression analysis because of the skewed distri-
bution and excess of zeros of the HJHS on its continuous scale.23
Multivariable logistic regression analysis was performed to
explore whether these determinants could explain possible dif-
ferences in the occurrence of ‘radiological arthropathy’ and func-
tional limitations (PS>3 and HAL total <95 as dependent vari-
able, respectively). We used logistic regression analysis to
explore whether FVIII, type 3 VWD, higher age, age at the first
joint bleed, or the cumulative number of joint bleeds were asso-
ciated with arthropathy (HJHS≥10 or PS>3) within the VWD-JB
group and whether arthropathy was associated with clinically
relevant joint pain (VAS mean >3) within the whole study
cohort. 
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Table 4. Associations between the Hemophilia Joint Health Score (HJHS), Pettersson Score (PS) and Hemophilia Activity List (HAL) and co-vari-
ables. A. Among 48 von Willebrand disease-joint bleed (VWD-JB) patients compared to 48 VWD controls (independent variable).
Dependent variable Co-variable Rate ratio 95% CI P
HJHS - 2.5 1.6-3.9 <0.01
BMI 2.4 1.6-3.8 <0.01
D-AIMS2-affect 2.9 1.9-4.7 <0.01
Relcom* 2.8 1.8-4.3 <0.01
Odds ratio
PS >3 - 7.7 1.6-36 0.01
BMI 7.7 1.6-37 0.01
D-AIMS2-affect 8.8 1.8-43 <0.01
Relcom* 8.5 1.7-42 <0.01
HAL <95 - 3.8 1.6-8.8 <0.01
BMI 3.6 1.5-8.6 <0.01
D-AIMS2-affect 4.6 1.9-12 <0.01
Relcom* 4.0 1.7-9.4 <0.01
B. Among 48 VWD-JB patients: exploration of possible predictors of arthropathy.
Dependent variable Co-variable Odds ratio 95% CI P
HJHS ≥10 FVIII <10 IU/dL¥ 4.6 1.3-16 0.02
Type 3 VWD 5.1 1.5-18 0.01
Type 3 VWD & FVIII¥ 6.9 0.8-57 0.07
Age 1.0 1.0-1.1 0.28
Age 1th JB<10 y 2.2 0.7-7.4 0.19
No. joint bleeds# 2.2 1.2-4.0 0.01
No. joint bleeds# & FVIII¥ 2.1 1.0-4.1 0.04
> 5 joint bleeds in at least one joint 7.9 2.0-31 <0.01
PS >3 FVIII <10 IU/dL¥ 10 1.9-53 <0.01
Type 3 VWD 7.8 1.8-35 <0.01
Type 3 VWD & FVIII¥ 6.8 0.6-84 0.14
Age 1.0 1.0-1.1 0.34
Age 1th JB <10 y 3.8 1.0-15 0.06
No. joint bleeds# 3.9 1.4-11 <0.01
No. joint bleeds# & FVIII¥ 3.4 1.2-10 0.02
> 5 joint bleeds in at least one joint 17 2-149 0.01
CI: Confidence Interval; HJHS: Hemophilia Joint Health Score;  no.: number; PS: Pettersson score; HAL: Hemophilia Activity List questionnaire; FVIII: historically lowest Factor VIII
level;  D-AIMS2: Dutch Arthritis Impact; JB: joint bleed; Relcom: relevant comborbidity. BMI: Body Mass Index. *Possible restricted motion due to a musculoskeletal disorder for
other medical reasons (excluding age-related osteoarthritis). ¥Historically lowest FVIII level. #Cumulative number of joint bleeds categorized (see Table 1). 
Results
Baseline characteristics
In total, 119 patients were screened for participation: 19
patients did not want to participate and 4 were excluded
on the basis of  the exclusion criteria (n=1) or because they
did not meet the inclusion criteria (n=3). A total of 48
VWD-JB patients and 48 VWD controls were included
with a mean age of 46 years (range 18-80). Most patients
had participated actively in the WiN study (95%: 44 of 48
VWD-JB patients and 47 of 48 VWD controls).2 Baseline
characteristics are presented in Table 1. Despite matching,
the median FVIII and VWF levels were lower in the VWD-
JB group, compared to the VWD control group (Table 1
and Online  Supplementary Table S1). This was due to the
wide range in age and clotting factor levels within the
original WiN cohort, the low correlation between VWF
and FVIII levels, and the relatively limited size of 804 sub-
jects.2 Furthermore, due to the matching of clotting factor
levels instead of subtype, more VWD-JB patients had type
3 VWD (19 vs. 3 VWD controls, P<0.01) (Table 1). 
Body structure and function: occurrence and severity
of arthropathy  
The VWD-JB patients were four times more likely to
have developed arthropathy compared to the VWD con-
trols (HJHS≥10 or PS>3 of one or more joints: OR 3.8,
95%CI: 1.4-10). This difference became somewhat
stronger after correcting for the unverified joint bleeds in
the control group (OR 6.8, 95%CI: 1.8-25). Arthropathy,
as detected by HJHS≥10, occurred in 40% of the VWD-JB
patients compared to 10% of the VWD controls (OR 5.8
95%CI: 2.0-17, P<0.01). VWD-JB patients had more
severe and more often radiological joint abnormalities
compared to the controls, especially in the ankles (Online
Supplementary Table S2). Arthropathy based on X-rays
(PS>3 of one or more joints) was found in 25% of the
VWD-JB patients compared to 4% of the VWD controls
(OR 7.7 95%CI: 1.6-37, P=0.01). None of the VWD-JB
patients had a PS>3 in a contralateral joint without prior
bleeds.
Self-perceived functional abilities and Figure 8 walk
test 
VWD-JB patients reported more functional limitations
in the HAL, compared to the VWD controls (median HAL
total score 88 vs. 100) (Table 2). Some functional limita-
tions (HAL total score <95) were reported by 67% of the
VWD-JB patients compared to 35% of the controls (HAL
total <95, OR 3.8; 95%CI: 1.6-8.8, P<0.01). No significant
difference in performance according to the modified
Figure 8 walk tests was found between the VWD-JB
patients and VWD controls (Table 2). However, the VWD-
JB patients with arthropathy did perform worse on the
Figure 8 test compared to those without arthropathy
(Table 3).
IPA, environmental and personal factors, joint pain 
No significant differences in the IPA score (participation
questionnaire) and level of anxiety or mood were found
between the VWD-JB patients and VWD controls (Table
2).  However, the VWD-JB patients with arthropathy had
a lower score on the IPA compared those without
arthropathy, corresponding to less social participation
(Table 3). 
Clotting factor prophylaxis because of joint bleeds was
used by 58% (11 of 19) of the VWD-JB patients with
arthropathy (HJHS≥10). BMI, relevant musculoskeletal
comorbidity or mood/anxiety did not influence the differ-
ence in arthropathy between the VWD-JB patients and
VWD controls in multivariable analysis (Table 4A). 
Clinically relevant joint pain (VAS mean >3 of ≥1 joints)
was reported by 36% of the VWD-JB patients compared
to 19% of the VWD controls (OR 2.4 95%CI:0.9-6.1,
P=0.07) (Table 2). Within the VWD-JB patients, arthropa-
thy HJHS≥10 was strongly associated with clinically rele-
vant joint pain (OR 18 95%CI: 3.9-84, P<0.01).
Arthropathy PS>3 showed a weaker association with clin-
ically relevant joint pain in the VWD-JB patients (OR 3.6
95%CI: 0.93-14, P=0.06). Fifty-nine percent (10 of 17) of
the VWD-JB patients with clinically relevant joint pain
used or had used pain medication for joint pain.
Predictors of arthropathy 
Within the VWD controls, the patients with arthropa-
thy HJHS≥10 were significantly older compared to the
VWD controls with HJHS<10 (median age 63 vs. 46 years,
P=0.03). In contrast, this age difference was not found
within the VWD-JB patients (median age 50 in the VWD-
JB patients with arthropathy vs. 44 in those without
arthropathy, P=0.38) (Table 3). More females than males
had arthropathy within the VWD-JB patients (Table 3).
The occurrence of arthropathy within the VWD-JB
patients was associated with the cumulative number of
joint bleeds. A low FVIII level less than 10 IU/dL at VWD
diagnosis (in all 19 type 3, one type 2, and 3 type 1 VWD-
JB patients) was also associated with the occurrence of
arthropathy. Type 3 VWD was associated with arthropa-
thy, but not independent from FVIII levels (Table 4B).
Patients who had their first joint bleed under the age of 11
years showed a trend towards the occurrence of ‘radiolog-
ical arthropathy’ more often compared to the VWD-JB
patients who had their first joint bleed over ten years of
age (OR 3.8; 95%CI: 1.0-15, P=0.06). The VWD-JB
patients who had a history of more than 5 joint bleeds in
at least one joint (n=25 of 48) were also significantly more
likely to have developed arthropathy (Table 4B). In a logis-
tic regression model, the difference in the occurrence of
arthropathy between the patients and controls was
dependent on bleeding and not on FVIII levels: after
adjustment for a history of more than 5 joint bleeds in at
least one joint the OR changed from 3.8 to 1.8 (95%CI: 1-
12, P=0.36), but it remained stable after adjustment for
historically lowest FVIII level at 3.5 (95%CI: 1.3-9.5,
P=0.02). 
Discussion
This nested case-control study demonstrates that 40%
of patients with VWD and documented treatment for
joint bleeds (VWD-JB patients) have arthropathy at phys-
ical examination (HJHS ≥10) and 25% ‘radiological
arthropathy’ of ankles, knees or elbows (PS>3).
Arthropathy occurred significantly less often in matched
patients with VWD who had never received treatment for
a joint bleed (10% HJHS≥10 and 4% PS>3). Arthropathy
is related to clinically relevant joint pain and less social
participation. The VWD-JB patients also reported signifi-
cantly more functional limitations in the HAL question-
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naire, compared to the VWD controls. Within the VWD-
JB patient group, the most important predictors of the
development of arthropathy were a FVIII level <10 IU/dL
and the cumulative number of joint bleeds. 
Comparing VWD-JB patients to matched VWD controls
without a relevant history of joint bleeds allowed us to get
a good impression of the consequences of joint bleeds in
VWD, independently of  the burden of VWD itself and
age-related osteoarthritis. More X-rays were taken from
the VWD-JB patients compared to VWD controls, which
could have led to a potential overestimation of the differ-
ence in the occurrence of ‘radiological arthropathy’
between the two groups. However, only one of the VWD
controls had a PS>3 not related to joint bleeding. None of
the VWD-JB patients had a PS>3 based on X-rays of a con-
tralateral joint without a history of joint bleeds. 
For the first time, we used the HJHS to measure
arthropathy in VWD. The HJHS has been validated to
assess joint outcome in hemophilia.22 The cut off of
HJHS≥10 to define arthropathy has been used in hemo-
philia patients with a lower mean age of 25 years.11 We
found a median HJHS of 10 in VWD patients with a his-
tory of more than 5 joint bleeds within our validation
study (on the same VWD cohort) which  supports the
rationale of a similar cut off for arthropathy in VWD.12
Nevertheless, we also observed 5 cases of arthropathy
HJHS≥10 within the VWD controls, associated with older
age. A higher cut off to define arthropathy would lead to
loss of sensitivity. However, the incidence of osteoarthritis
increases with age, especially after  50 years of age.24 An
age-specific HJHS cut off to define arthropathy could be
the subject of further study.
Recall and information bias, including misclassification
of joint symptoms for joint bleeds, probably hampered the
reliability of the data on the cumulative number of joint
bleeds.25 The occurrence of unverified joint bleeds in 14
VWD controls led to an underestimation of the difference
in the occurrence of arthropathy between the VWD-JB
patients and VWD controls. Further study is needed to
find a better threshold for severity of joint bleeds to cause
arthropathy than verification by documentation on treat-
ment for joint bleeds. The strong association between a
HJHS≥10 and clinically relevant joint pain could partly be
explained by assigning points for joint pain in the HJHS
assessment (max. 1 point for each of 6 joints). 
This study is the first to report functional consequences
of joint bleeds in VWD. It appears that the prevalence of
arthropathy due to joint bleeds in the total population of
patients with moderate to severe VWD is less than 6%,
since 44 of the VWD-JB patients within the current study
were selected from the original WiN cohort (n=804).
However, not all eligible WiN patients participated in the
current study. Literature on joint damage due to joint bleeds
is scarce in VWD and arthropathy has not been well
defined.5 More studies on arthropathy should be conducted
in other VWD cohorts to confirm the validity of our results. 
In hemophilia, progressive arthropathy predominantly
occurs when patients report more than 5 joint bleeds
before the start of prophylaxis.26 A history of more than 5
treated joint bleeds was also associated with arthropathy
in the current study, which is in accordance with the find-
ings of our cross-sectional study.4 As in hemophilia, we
found VWD arthropathy mostly in the ankle joints (19%
of VWD JB patients had a PS ankle >3).22 In mild and mod-
erate hemophilia, ankle arthropathy, less strictly defined
as a PS>0, occurred in 48% of the patients and was also
associated with FVIII levels less than 10 IU/dL and with
ankle bleeding at a young age.27
The HJHS is suitable to detect arthropathy in VWD and
physiotherapists should be involved in patient care after
joint bleeds, as in hemophilia, to obtain complete recov-
ery.28 To get a better impression of the prevalence of
arthropathy in VWD, upfront joint assessment is needed
in future population studies on VWD, especially those
VWD patients with type 3 VWD, low FVIII levels, and
those who received prior treatment for joint bleeds. 
The VWD patients with the poorest joint outcome were
also the most heavily treated patients. Fifty-eight percent
of the patients with an HJHS≥10 had used clotting factor
prophylaxis. However, the association of arthropathy
with clinically relevant joint pain, lower health-related
quality of life,4 functional limitations and less social partic-
ipation, suggests that there might be room for more inten-
sive treatment of joint bleeds in VWD. In accordance with
the ICF model, this should include a rehabilitation pro-
gram aimed at full functional recovery. It remains to be
determined whether more intensive prophylaxis to pre-
vent arthropathy and improve participation in VWD
would be cost-effective.29 
In conclusion, arthropathy as detected by the
Hemophilia Joint Health Score occurs in almost half of
VWD patients treated for joint bleeds; this is consistent
with more radiological joint abnormalities compared to
matched VWD controls without a relevant history of joint
bleeds. VWD patients with arthropathy reported more
functional limitations and less social participation com-
pared to those without arthropathy, and clinically relevant
joint pain in the majority of cases. 
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